Clinical Trial Update: Efficacy and Safety of Oral Immunotherapy With GcMAF in Hospitalized Patients With COVID-19 Pneumonia [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating oral immunotherapy with GcMAF in hospitalized COVID-19 pneumonia patients reports efficacy and safety data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Drugs mentioned

• GcMAF (GcMAF)

Snippet

Sponsor: Dr. Spadera Lucrezia | Conditions: COVID-19 Pneumonia | Phase 2 | Status: COMPLETED